PPT-Hepatocellular Carcinoma

Abby Siegel MD MS Columbia University CoChair SWOG Hepatobiliary Committee NCI Task Force Hepatobiliary Cancers Outline Epidemiology Biology StagingPrognosisManagement Future of Targeted Therapy. Diagnosis and Management. Pippa. Newell, M.D.. Medical Director, Liver Cancer Program. Providence . Cancer Center, Portland. Hepatobiliary. Surgeon. The Oregon Clinic. philippa.newell@providence.org. Hilda T Marima- Matarira. Professor of Chemical Pathology. University of Zimbabwe. Objectives. To . evaluate the clinical utility of biochemical . tests. , . ie.. Alpha-Fetoprotein . (AFP) , . Alkaline Phosphatase . Richa Shukla. Faculty mentor: Dr. Sahil Mittal. February 12, 2015. Case discussion. Reason for presentation: Abdominal pain. 41F with medical history significant for HLD, HTN and DM. Presented to ED with 6 months of waxing and waning RUQ pain, worse over 3-4 weeks prior to presentation. risk factors and pathogenesis. Dr Richard Phillips. KNUST/KATH. Introduction. 0.25-1.2 million . cases worldwide per . year. 5. th. most common human cancer. . 80% of burden in developing countries. Richa Shukla. Faculty mentor: Dr. Sahil Mittal. February 12, 2015. Case discussion. Reason for presentation: Abdominal pain. 41F with medical history significant for HLD, HTN and DM. Presented to ED with 6 months of waxing and waning RUQ pain, worse over 3-4 weeks prior to presentation. Authors. : . Federico Piñero. 1,11,12. , Fernando Rubinstein. 15. , . Sebastián. Marciano. 2. , Nora Fernández. 5. , Jorge Silva. 10. , . Yanina. Zambelo. 8. , Margarita Anders. 4. , . Alina. Zerega. Serum Squamous . Cell Carcinoma Antigen (SCCA) for Prediction of HCC Patients . Presented . By:. Sally Saad Mandour Esawy. Ass. . Lecturer of Clinical Pathology. National Liver Institute, . Menoufia. Curtis Barry, MD. UMASS ECHO. April 21, 2017. Ascites. The Development of Ascites. Revised Underfill. . Peripheral vasodilation occurs as the result of decreased hepatic clearance of vasodilators such as glucagon and NO. ● ● CBC with differential , liver function test ( LFTs ) , c reatinine , electrolytes , PT / INR , lipid profile , hemoglobin A 1 C , alpha - fetoprotein ( AFP ) ● Viral serologies if ISSN: 2640 - 2343 Conventional Transarterial Chemoembolization (TACE) of a Hepatocellular Carcinoma with Aberrant Extrahepatic Blood Supply using Balloon Microcath e ter for Flow Redirection Clin R 4874 Key words (MeSH)Carcinoma hepatocellularMagnetic resonance Liver neoplasms Palabras clave (DeCS)Carcinoma hepatocelularImagen por resonancia Neoplasias hepáticas Magnetic Resonance Imaging of th in Hepatocellular Carcinoma: . Real-World Experience and Treatment Sequencing with NASH/NAFLD Risk Factors. Sammy Saab, . MD, MPH, AGAF, FACG, FAASLD. Medical Director, Pfleger Liver Institute. Medical Director, Adult Liver Transplant Program. Hepatocellular Carcinoma. Risk factors for HCC. HBV – the most common causative risk factor. Increased risk :. Earlier infection. Higher DNA load (>2000 IU/L). Higher level of quant. . HbsAg. (>10,000 U/L).